Clinical implications of thymidylate synthetase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activity levels in colorectal carcinoma following radical resection and administration of adjuvant 5-FU chemotherapy

被引:15
作者
Ishikawa, Masashi [1 ,2 ]
Miyauchi, Takayuki [1 ]
Kashiwagi, Yutaka [1 ]
机构
[1] Natl Kochi Hosp, Dept Surg, Kochi, Japan
[2] Tokushima Red Cross Hosp 103 Irinokuchi, Dept Surg, Komatsushima City, Tokushima 7738502, Japan
关键词
D O I
10.1186/1471-2407-8-188
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bckground: A number of studies have investigated whether the activity levels of enzymes involved in 5-fluorouracil (5-FU) metabolism are prognostic factors for survival in patients with colorectal carcinoma. Most reports have examined thymidylate synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) in unresectable or metastatic cases, therefore it is unclear whether the activity of these enzymes is of prognostic value in colorectal cancer patients treated with radical resection and adjuvant chemotherapy with 5-FU. Methods: This study examined fresh frozen specimens of colorectal carcinoma from 40 patients who had undergone curative operation and were orally administered adjuvant tegafur/uracil (UFT) chemotherapy. TS, DPD and orotate phosphoribosyl transferase (OPRT) activities were assayed in cancer tissue and adjacent normal tissue and their association with clinicopathological variables was investigated. In addition, the relationships between TS, DPD and OPRT activities and patient survival were examined to determine whether any of these enzymes could be useful prognostic factors. Results: While there was no clear relationship between pathological findings and TS or DPD activity, OPRT activity was significantly lower in tumors with lymph node metastasis than in tumors lacking lymph node metastasis. Postoperative survival was significantly better in the groups with low TS activity and/or high OPRT activity. Conclusion: TS and OPRT activity levels in tumor tissue may be important prognostic factors for survival in Dukes' B and C colorectal carcinoma with radical resection and adjuvant chemotherapy with UFT.
引用
收藏
页数:7
相关论文
共 21 条
[1]  
Allegra CJ, 1999, CLIN CANCER RES, V5, P1947
[2]  
[Anonymous], 2002, JPN J CANC CHEMOTHER, V29, P413
[3]  
Cascinu S, 1999, CLIN CANCER RES, V5, P1996
[4]   Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil [J].
Ciaparrone, M. ;
Quirino, M. ;
Schinzari, G. ;
Zannoni, G. ;
Corsi, D. C. ;
Vecchio, F. M. ;
Cassano, A. ;
La Torre, G. ;
Barone, C. .
ONCOLOGY, 2006, 70 (05) :366-377
[5]   Thymidylate synthase expression in colorectal cancer:: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy [J].
Edler, D ;
Glimelius, B ;
Hallström, M ;
Jakobsen, A ;
Johnston, PG ;
Magnusson, I ;
Ragnhammar, P ;
Blomgren, H .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1721-1728
[6]  
Edler D, 2000, CLIN CANCER RES, V6, P488
[7]   Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma [J].
R. Fujii ;
A. Seshimo ;
S. Kameoka .
International Journal of Clinical Oncology, 2003, 8 (2) :72-78
[8]   Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo [J].
Fukushima, M ;
Fujioka, A ;
Uchida, J ;
Nakagawa, F ;
Takechi, T .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (13) :1681-1687
[9]   Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer [J].
Ichikawa, W ;
Uetake, H ;
Shirota, Y ;
Yamada, H ;
Takahashi, T ;
Nihei, Z ;
Sugihara, K ;
Sasaki, Y ;
Hirayama, R .
BRITISH JOURNAL OF CANCER, 2003, 89 (08) :1486-1492
[10]  
Ichikawa W, 2003, CLIN CANCER RES, V9, P786